Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as 1: Liothyronine Sodium Tablets
Liothyronine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Liothyronine Sodium Tablets, 50 mcg |
| 2 | ACTIVE_COMPARATOR | Cytomel® Tablets, 50 mcg |
| Name | Type | Description |
|---|---|---|
| 1: Liothyronine Sodium Tablets | DRUG | Liothyronine Sodium Tablets, 50 mcg 2 x 50 mcg, single-dose, fasting |
| 2: Cytomel® Tablets | DRUG | Cytomel® Tablets, 50 mcg 2 x 50 mcg, single-dose, fasting |
Inclusion Criteria: * healthy males and/or non-pregnant, non-lactating females, 18 years and older * able to swallow medication Exclusion Criteria: * institutionalized subjects * history of any significant disease * use of any prescription or OTC medications within 14 days prior to start of study...
Liothyronine is a small molecule drug developed by Viatris Inc. (ticker VTRS) and also known as Liothyronine Sodium Tablets. It is being studied in a Phase 1 clinical program. The specific medical conditions it is intended to treat have not been disclosed.
Liothyronine is developed by Viatris Inc., which trades under the ticker VTRS. The company is the sponsor behind the clinical development of Liothyronine Sodium Tablets.
Liothyronine is in Phase 1 clinical development. It is an investigational small molecule and is not described as approved. One Phase 1 trial has been completed, and no trials are currently active.
Liothyronine has been studied in one completed Phase 1 trial, NCT00978055, titled a fasting study of Liothyronine Sodium Tablets (50 mcg) to Cytomel tablets (50 mcg). The trial enrolled 31 healthy adult volunteers in the United States, was randomized, and used an active control.
Yes. Liothyronine Sodium Tablets is an alternative name for liothyronine, so searches for either name refer to the same drug asset developed by Viatris Inc. under ticker VTRS.
The completed Phase 1 trial NCT00978055 was a randomized, active-controlled fasting study comparing Liothyronine Sodium Tablets (50 mcg) with Cytomel tablets (50 mcg). It enrolled 31 healthy volunteers aged 18 years and older in the United States and was not double blinded.